Immuron Ltd Files January 2025 Report (6-K)

TL;DR

Immuron Ltd (IMRN) filed its 6-K for Jan 2025, confirming 20-F filing and Australian HQ.

AI Summary

Immuron Limited filed a Form 6-K on January 14, 2025, reporting its activities for the month of January 2025. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. The company's principal executive office is located in Carlton South, Victoria, Australia.

Why It Matters

This filing provides an update on Immuron Limited's regulatory reporting status and confirms its adherence to SEC requirements for foreign private issuers.

Risk Assessment

Risk Level: low — This is a routine reporting form for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

• Immuron Limited (company) — Registrant
• Form 6-K (document) — Filing type
• Form 20-F (document) — Annual report filing
• January 2025 (date) — Reporting period
• Carlton South, Victoria, Australia (location) — Principal executive office

FAQ

Filing Documents

• ea0227578-6k_immuron.htm (6-K) — 12KB
• ea022757801ex99-1_immuron.htm (EX-99.1) — 30KB
• ex99-1_001.jpg (GRAPHIC) — 5KB
• ex99-1_002.jpg (GRAPHIC) — 30KB
• ex99-1_003.jpg (GRAPHIC) — 10KB
• 0001213900-25-003165.txt ( ) — 106KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- IMMURON LIMITED EXPLANATORY NOTE Immuron Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on January 14, 2025 titled: - “Immuron Announces Travelan Clinical Trial Update” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Immuron Announces Travelan Clinical Trial Update 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMURON LIMITED Date: January 14 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR